Lipocine's Phase 2 study of LPCN 1148 for cirrhosis management met primary endpoints, showing increased SMI and fewer OHE events.
Lipocine reports positive Week 52 results from a Phase 2 study of LPCN 1148, an oral drug candidate for cirrhosis management. The study achieved primary endpoints, demonstrating a significant increase in Skeletal Muscle Index (SMI) and fewer OHE events in patients on LPCN 1148 therapy compared to placebo. Lipocine plans to meet with the FDA to discuss the development path towards New Drug Application (NDA) filing.
March 28, 2024
4 Articles